Pfizer is making a $15.2 billion bet on the drug industry’s new, more elite class of generics: costly, complex copies of already expensive biotech drugs. In its offer on Thursday to buy Hospira for $90 a share, or $17 billion including debt, Pfizer is paying…
Read More
Latest in Drugs Archives - Access International Patent
More Articles
On March 25, Indiana Governor Mike Pence signed legislation (Senate Bill 262) that will allow pharmacists in Indiana to substitute an interchangeable biosimilar product for a prescribed biological product if certain conditions are met. Senate Bill 262, which was authored by Sen. Brandt Hershman (R)…
Read More